Affiliations: [a] National Institute for Longevity Sciences, NCGG, 36-3 Gengo, Morioka, Obu City, Aichi 474-8522, Japan | [b] Center for Neurological Diseases, Brigham & Women's Hospital, Harvard Institute of Medicine, 77 Avenue Louis Pasteur, HIM730, Boston, MA02115, USA | [c] Department of Molecular Therapy, National Institute of Neuroscience, NCNP, 4-1-1 Ogawa-higashi, Kodaira City, Tokyo 187-8502, Japan | [d] Department of Molecular Genetics and Biochemistry, Gene Therapy Center, and Duchenne Muscular Dystrophy Research Center, University of Pittsburgh, Pittsburgh, PA 15261, USA
Correspondence:
[*]
Corresponding author: Hideo Hara, MD. or Takeshi Tabira, MD National Institute for Longevity Sciences, NCGG, 36-3 Gengo, Morioka, Obu City, Aichi 474-8522, Japan. Tel.: +81 562 46 2311; Fax: +81 562 45 0184; E-mail: hhara@nils.go.jp or tabira@nils.go.jp.
Abstract: A new oral vaccine for Alzheimer's disease was developed using recombinant adeno-associated virus vector carrying Aβ cDNA (AAV/Aβ). Oral administration of the vaccine without adjuvant induced the expression and secretion of Aβ1–43 or Aβ1–21 in the epithelial cell layer of the intestine in amyloid precursor protein transgenic mice. Serum antibody levels were elevated for more than six months, while T cell proliferative responses to Aβ was not detected. Brain Aβ burden was significantly decreased compared to the control without inflammatory changes. This oral AAV/Aβ vaccine seems to be promising for prevention and treatment of Alzheimer's disease.
